尿液类固醇代谢组可无创诊断和分期非酒精性脂肪性肝病
该研究纳入275例受试者(121例活检证实NAFLD、48例酒精性肝硬化、106例对照),采用气相色谱-质谱联用和机器学习GMLVQ分析尿液类固醇代谢组。结果显示该方法能极好区分早期(F0-F2)与进展期(F3-F4)纤维化(AUC 0.92),近乎完美区分对照与进展期纤维化NAFLD(AUC 0.99)及NAFLD肝硬化(AUC 1.0),并可区分NAFLD肝硬化与酒精性肝硬化(AUC 0.83)。
要点
- 尿液类固醇代谢组结合GMLVQ可无创区分NAFLD早期与进展期纤维化,AUC达0.92。
- 该方法近乎完美区分对照与进展期纤维化NAFLD及NAFLD肝硬化。
- 可区分NAFLD肝硬化与酒精性肝硬化,AUC为0.83。
核心结论
- 基于尿液类固醇代谢组的GMLVQ分析可作为无创生物标志物策略,用于NAFLD纤维化分期及筛查。
研究设计与样本
- 研究纳入275例受试者,包括121例活检证实的NAFLD、48例酒精性肝硬化和106例对照。
- 采用气相色谱-质谱联用(GC-MS)分析尿液类固醇代谢组,并结合机器学习GMLVQ分析。
临床怎么用
- 该无创尿液生物标志物有望在二级医疗和初级医疗中用于NAFLD纤维化分期和筛查,减少肝活检需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The development of accurate, non-invasive markers to diagnose and stage non-alcoholic fatty liver disease (NAFLD) is critical to reduce the need for an invasive liver biopsy and to identify patients who are at the highest risk of hepatic and cardio-metabolic complications. Disruption of steroid hormone metabolic pathways has been described in patients with NAFLD. AIM(S): To assess the hypothesis that assessment of the urinary steroid metabolome may provide a novel, non-invasive biomarker strategy to stage NAFLD. METHODS: We analysed the urinary steroid metabolome in 275 subjects (121 with biopsy-proven NAFLD, 48 with alcohol-related cirrhosis and 106 controls), using gas chromatography-mass spectrometry (GC-MS) coupled with machine learning-based Generalised Matrix Learning Vector Quantisation (GMLVQ) analysis. RESULTS: Generalised Matrix Learning Vector Quantisation analysis achieved excellent separation of early (F0-F2) from advanced (F3-F4) fibrosis (AUC receiver operating characteristics [ROC]: 0.92 [0.91-0.94]). Furthermore, there was near perfect separation of controls from patients with advanced fibrotic NAFLD (AUC ROC = 0.99 [0.98-0.99]) and from those with NAFLD cirrhosis (AUC ROC = 1.0 [1.0-1.0]). This approach was also able to distinguish patients with NAFLD cirrhosis from those with alcohol-related cirrhosis (AUC ROC = 0.83 [0.81-0.85]). CONCLUSIONS: Unbiased GMLVQ analysis of the urinary steroid metabolome offers excellent potential as a non-invasive biomarker approach to stage NAFLD fibrosis as well as to screen for NAFLD. A highly sensitive and specific urinary biomarker is likely to have clinical utility both in secondary care and in the broader general population within primary care and could significantly decrease the need for liver biopsy.
引用
- Moolla A, de Boer J, Pavlov D, et al. Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolome. Aliment Pharmacol Ther. 2020. PMID: 32298002. doi:10.1111/apt.15710
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。